Deborah Lannigan

Prof. Dr. Deborah Lannigan

1. Departments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA</br> 2. Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA</br> 3. Department of Biomedical Engineering, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
KLKatarzyna A. Ludwik
Katarzyna A. Ludwik
JCJ. Preston Campbell
J. Preston Campbell
MLMingzong Li
Mingzong Li
YLYu Li
Yu Li
ZSZachary M. Sandusky
Zachary M. Sandusky
Deborah LanniganDeborah Lannigan
Deborah Lannigan
Metastatic breast cancer is an incurable disease and identification of novel therapeutic opportunities is vital. Triple-negative breast cancer (TNBC) frequently metastasizes and high levels of activated p90RSK (RSK), a downstream MEK-ERK1/2 effector, are found in TNBC. We demonstrate, using direct pharmacologic and genetic inhibition of RSK1/2, that these kinases contribute to the TNBC metastatic process in vivo. Kinase profiling showed that RSK1 and RSK2 are the predominant kinases targeted by the new inhibitor, which is based on the natural product SL0101. Further evidence for selectivity was provided by the observations that silencing RSK1 and RSK2 eliminated the ability of the analogue to further inhibit survival or proliferation of a TNBC cell line. In vivo, the new derivative was as effective as the FDA-approved MEK inhibitor trametinib in reducing the establishment of metastatic foci. Importantly, inhibition of RSK1/2 did not result in activation of AKT, which is known to limit the efficacy of MEK inhibitors in the clinic. Our results demonstrate that RSK is a major contributor to the TNBC metastatic program and provide preclinical proof-of-concept for the efficacy of the novel SL0101 analogue in vivo. Mol Cancer Ther; 15(11); 2598–608. ©2016 AACR.

12 December 2014 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
MLMingzong Li
Mingzong Li
YLYu Li
Yu Li
RMRoman M. Mrozowski
Roman M. Mrozowski
ZSZachary M. Sandusky
Zachary M. Sandusky
MSMingde Shan
Mingde Shan
George A O'DohertyGeorge A O'Doherty
George A O'Doherty
The Ser/Thr protein kinase, RSK, is associated with oncogenesis, and therefore, there are ongoing efforts to develop RSK inhibitors that are suitable for use in vivo. SL0101 is a natural product that demonstrates selectivity for RSK inhibition. However, SL0101 has a short biological half-life in vivo. To address this issue we designed a set of eight cyclitol analogues, which should be resistant to acid catalyzed anomeric bond hydrolysis. The analogues were synthesized and evaluated for their ability to selectively inhibit RSK in vitro and in cell-based assays. All the analogues were prepared using a stereodivergent palladium-catalyzed glycosylation/cyclitolization for installing the aglycon. The l-cyclitol analogues were found to inhibit RSK2 in in vitro kinase activity with a similar efficacy to that of SL0101, however, the analogues were not specific for RSK in cell-based assays. In contrast, the d-isomers showed no RSK inhibitory activity in in vitro kinase assay.

25 April 2017 in Organic Letters
Verified
Journal Article
Closed access
MLMingzong Li
Mingzong Li
YLYu Li
Yu Li
KLKatarzyna A. Ludwik
Katarzyna A. Ludwik
ZSZachary M. Sandusky
Zachary M. Sandusky
Deborah LanniganDeborah Lannigan
Deborah Lannigan
George A O'DohertyGeorge A O'Doherty
George A O'Doherty

3 January 2013 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RMRoman M. Mrozowski
Roman M. Mrozowski
RVRajender Vemula
Rajender Vemula
BWBulan Wu
Bulan Wu
QZQi Zhang
Qi Zhang
BSBenjamin R. Schroeder
Benjamin R. Schroeder
Deborah LanniganDeborah Lannigan
Deborah Lannigan

19 July 2016 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
KLKatarzyna A. Ludwik
Katarzyna A. Ludwik
Deborah LanniganDeborah Lannigan
Deborah Lannigan
Introduction: The p90 ribosomal S6 kinases (RSK) are a family of Ser/Thr protein kinases that are downstream effectors of MEK1/2-ERK1/2. Increased RSK activation is implicated in the etiology of multiple pathologies, including numerous types of cancers, cardiovascular disease, liver and lung fibrosis, and infections. Areas covered: The review summarizes the patent and scientific literature on small molecule modulators of RSK and their potential use as therapeutics. The patents were identified using World Intellectual Property Organization and United States Patent and Trademark Office databases. The compounds described are predominantly RSK inhibitors, but a RSK activator is also described. The majority of the inhibitors are not RSK-specific. Expert opinion: Based on the overwhelming evidence that RSK is involved in a number of diseases that have high mortalities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use. MEK1/2 inhibitors are in the clinic, but the efficacy of these compounds appears to be limited by their side effects. We hypothesize that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulate fewer effectors.

5 November 2014 in Organic Letters
Verified
Journal Article
Open access
RMRoman M. Mrozowski
Roman M. Mrozowski
ZSZachary M. Sandusky
Zachary M. Sandusky
RVRajender Vemula
Rajender Vemula
BWBulan Wu
Bulan Wu
QZQi Zhang
Qi Zhang
George A O'DohertyGeorge A O'Doherty
George A O'Doherty
In an effort to improve upon the in vivo half-life of the known ribosomal s6 kinase (RSK) inhibitor SL0101, C4″-amide/C6″-alkyl substituted analogues of SL0101 were synthesized and evaluated in cell-based assays. The analogues were prepared using a de novo asymmetric synthetic approach, which featured Pd-π-allylic catalyzed glycosylation for the introduction of a C4″-azido group. Surprisingly replacement of the C4″-acetate with a C4″-amide resulted in analogues that were no longer specific for RSK in cell-based assays.